Table_2_Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2.DOCX
Objective: Limited data are available regarding the rates and risk factors of severe to serious adverse reactions (ARs) to the ChAdOx1 nCoV-19 vaccine.
Methods: Eligible participants were healthcare workers who received their first dose of the ChAdOx1 nCoV-19 vaccine in either of two university hospitals in Seoul, Korea. We evaluated the type and severity of ARs 7 days after the first dose of the ChAdOx1 nCoV-19 vaccine using a questionnaire survey delivered via a smartphone application link.
Results: Among the 1,603 participants who completed the survey, 684 (42.7%) participants experienced any kind of grade 3 to grade 4 AR. Being young (adjusted odds ratio [OR] for age 21–30 years = 2.49, 95% confidence interval [CI] = 1.75–3.56; adjusted OR for 31–40 years = 1.78, 95% CI = 1.22–2.62; adjusted OR for 41–50 years = 1.47, 95% CI = 1.03–2.11), being female (adjusted OR = 2.16. 95% CI = 1.62–2.89), and being underweight (adjusted OR = 1.61, 95% CI = 1.02–2.55) were identified as risk factors for grade 3 to grade 4 ARs. Among comorbidities, only diabetes mellitus (adjusted OR = 2.36, 95% CI = 1.03–5.53) was identified as a risk factor. When stratified by the type of AR, being young and being female were risk factors for both local and systemic grade 3 to grade 4 ARs.
Conclusions: Being young, female, or underweight and having diabetes mellitus were associated with an increased risk of developing grade 3 to grade 4 ARs after receiving the first dose of the ChAdOx1 nCoV-19 vaccine.
History
References
- https://doi.org//10.1038/d41586-020-01221-y
- https://doi.org//10.1056/NEJMoa2104840
- https://doi.org//10.1016/j.toxrep.2021.04.003
- https://doi.org//10.22541/au.160916124.47621341/v1
- https://doi.org//10.1016/S0140-6736%2820%2931604-4
- https://doi.org//10.1016/S0140-6736%2820%2932466-1
- https://doi.org//10.1016/S0140-6736%2820%2932661-1
- https://doi.org//10.1016/S0140-6736%2821%2900432-3
- https://doi.org//10.3346/jkms.2021.36.e107
- https://doi.org//10.3346/jkms.2021.36.e110
- https://doi.org//10.3346/jkms.2021.36.e115
- https://doi.org//10.3346/jkms.2021.36.e114
- https://doi.org//10.3803/EnM.2014.29.4.405
- https://doi.org//10.1056/NEJMoa2028436
- https://doi.org//10.1101/2021.02.24.21251664
- https://doi.org//10.15585/mmwr.mm7002e1
- https://doi.org//10.1016/j.jaad.2021.03.092
- https://doi.org//10.1001/jama.2021.1967
- https://doi.org//10.1002/bab.2076.
- https://doi.org//10.1016/j.dsx.2021.02.026
- https://doi.org//10.1101/2021.02.26.21252096
Usage metrics
Read the peer-reviewed publication
Categories
- Radiology and Organ Imaging
- Foetal Development and Medicine
- Obstetrics and Gynaecology
- Primary Health Care
- Medical and Health Sciences not elsewhere classified
- Dermatology
- Emergency Medicine
- Gastroenterology and Hepatology
- Geriatrics and Gerontology
- Intensive Care
- Medical Genetics (excl. Cancer Genetics)
- Nephrology and Urology
- Nuclear Medicine
- Orthopaedics
- Otorhinolaryngology
- Pathology (excl. Oral Pathology)
- Family Care